Tag - Psycheceuticals

Developments

FSD Pharma to acquire Lucid Psycheceuticals

FSD Pharma (NASDAQ:HUGE; CSE:HUGE; FRA:0K9A) agreed to acquire all the shares of closely-held, Lucid Psycheceuticals, for approximately $9-million in FSD Pharma stock. “Lucid has successfully developed a strong...

August 25, 2021

Feature

Lucid Psycheceuticals focusing on Total Brain Health

Lucid Psycheceuticals’ next generation approach to total brain health is targeting the interface between mental health and neurodegenerative disorders with therapeutic products inspired by psychedelics and new chemical...

August 17, 2021

Developments

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Lucid Psycheceuticals inked a world-wide license agreement with Toronto’s University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications...

June 14, 2021

Tag - Psycheceuticals

FSD Pharma to acquire Lucid Psycheceuticals

Lucid Psycheceuticals focusing on Total Brain Health

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

General

More